To understand why GHRP-2 is an interesting research tool, you need to see that the pituitary gland receives the “GH secretion” signal through more than one channel. The somatotropic cell of the anterior pituitary has at least two separate receptors on its surface that stimulate the release of growth hormone: GHRH receptor and growth hormone secretion receptor type 1a (GHS-R1a), i.e. ghrelin receptor.
These are two different proteins, two different intracellular cascades and two different physiological signals – which converge on the same end result, the release of GH from secretory granules. GHRP-2 works on this second arm – ghrelin arm.
Ghrelin is an endogenous peptide hormone discovered as a natural ligand of the GHS-R1a receptor; serves as a hunger signal and at the same time a powerful stimulator of growth hormone release. GH-releasing peptides (GHRPs) are synthetic molecules that mimic ghrelin at the level of this receptor – except that they were designed with a pharmacological profile that is different from the full ghrelin molecule.
GHRP-2 is a classic representative of this group: a strong GHS-R1a agonist with a clear GH-secretagogic profile and a limited, compared to GHRP-6, effect on appetite. In the Endogenic catalog, GHRP-2 belongs to a broader family growth hormone-increasing peptides — GHRP and GHRH secretagogues acting on the somatotropic axis.
Ghrelin receptor (GHS-R1a) is a Gq protein-coupled receptor. Its stimulation activates phospholipase C, increases intracellular calcium and leads to the release of GH – in a way separate from GHRH. Importantly, the ghrelin arm additionally suppresses somatostatin (inhibiting hormone) and enhances its own GHRH action. Physiologically, secretagogues acting on this receptor influence frequency and pulsatility GH release, and in the case of strong GHRPs – such as GHRP-2 – also on the amplitude of a single burst.
The pulsatile nature of GH secretion is the main physiological detail here – and the reason why the Endogenic line singles out GHRP-2 as a research tool.
Unlike exogenous, recombinant growth hormone, which floods the circulation with a flat, non-physiological concentration, the secretagogue stimulates own pituitary to release GH in a way that preserves the pulsatile signal architecture – involving the somatostatin feedback loop. This “endogenous, pulsatile” release pattern is the subject of research on the physiology of the GH/IGF-1 axis, the regulation of slow-wave sleep (in which the strongest nocturnal GH pulse occurs), and the differences between secretagogue stimulation and the administration of recombinant GH. The pharmacology of growth hormone secretagogues includes two large classes of tools:
- GHRH analogues — mimic the endogenous GH-releasing hormone, stimulate the GHRH receptor, increase the pulse amplitude (CJC-1295, sermorelin, tesamorelin)
- GH-releasing peptides (GHRP) and ghrelin mimetics — stimulate the GHS-R1a ghrelin receptor, increase the pulse rate and suppress somatostatin (GHRP-2, GHRP-6, Ipamorelin, hexarelin)
Within the GHRP class, individual molecules differ in the strength of GH stimulation and profile of accompanying activities — influence on appetite (ghrelin axis), cortisol, prolactin and ACTH (stress axis). It is these differences – and not the receptor mechanism itself, common to the entire class – that define the position of each GHRP in the literature and make GHRP-2 a distinct tool for comparative research.